TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Orthocell Ltd ( (AU:OCC) ) just unveiled an update.
Orthocell Limited reported a record revenue of $3 million for the September 2025 quarter, marking a 9.1% increase from the previous quarter. This growth is attributed to the expanding market penetration of its nerve repair product, Remplir™, particularly in Australia and Singapore. The company is poised for further revenue growth with the anticipated increase in Remplir sales in the US and Canada, supported by a strong distributor network and robust cash reserves of $27 million. The strategic expansion into these markets is expected to significantly enhance Orthocell’s industry positioning and stakeholder value.
The most recent analyst rating on (AU:OCC) stock is a Hold with a A$1.50 price target. To see the full list of analyst forecasts on Orthocell Ltd stock, see the AU:OCC Stock Forecast page.
More about Orthocell Ltd
Orthocell Limited is a regenerative medicine company specializing in nerve repair products. The company focuses on the development and commercialization of innovative medical solutions, with its primary product, Remplir™, gaining market traction in Australia, Singapore, and the United States.
Average Trading Volume: 580,148
Technical Sentiment Signal: Strong Buy
Current Market Cap: A$306.6M
For detailed information about OCC stock, go to TipRanks’ Stock Analysis page.